Lisata Therapeutics Q1 2024 GAAP EPS $(0.65) Beats $(0.72) Estimate
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics (NASDAQ:LSTA) reported Q1 2024 GAAP EPS of $(0.65), surpassing the $(0.72) estimate, marking a 9.72% beat and a 15.58% improvement over the previous year's $(0.77) per share loss.
May 09, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics reported a smaller than expected Q1 2024 loss of $(0.65) per share, beating estimates and showing improvement over the previous year.
Beating EPS estimates typically has a positive impact on investor sentiment, suggesting a potential short-term uptick in LSTA's stock price. The improvement over the previous year's performance further strengthens the case for a positive market reaction.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100